AR095081A1 - Compuestos químicos - Google Patents

Compuestos químicos

Info

Publication number
AR095081A1
AR095081A1 ARP140100782A ARP140100782A AR095081A1 AR 095081 A1 AR095081 A1 AR 095081A1 AR P140100782 A ARP140100782 A AR P140100782A AR P140100782 A ARP140100782 A AR P140100782A AR 095081 A1 AR095081 A1 AR 095081A1
Authority
AR
Argentina
Prior art keywords
polymers
compositions
chemical compounds
useful
agent
Prior art date
Application number
ARP140100782A
Other languages
English (en)
Inventor
Borrs Gmez Salvador
Ramos Prez Victor
Segovia Ramos Nathaly
Dosta Pons Pere
Original Assignee
Inst Químic De Sarrià Cets Fundació Privada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Químic De Sarrià Cets Fundació Privada filed Critical Inst Químic De Sarrià Cets Fundació Privada
Publication of AR095081A1 publication Critical patent/AR095081A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/028—Polyamidoamines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen polímeros que son poli(b-amino ésteres) (PBAE) modificados con al menos un oligopéptido. Los polímeros se pueden usar en cualquier campo en los cuales se ha encontrado que los polímeros son útiles, con inclusión de los campos médicos; en particular, en la entrega de drogas. Los polímeros son particularmente útiles para entregar un polinucléotido tal como ADN, ARN y ARNip, una molécula pequeña o una proteína. También se describen composiciones que comprenden dichos polímeros y un agente activo, métodos para encapsular un agente en una matriz de dichos polímeros, y dichos polímeros y composiciones para uso en medicina.
ARP140100782A 2013-03-08 2014-03-10 Compuestos químicos AR095081A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1304245.2A GB201304245D0 (en) 2013-03-08 2013-03-08 Chemical compounds

Publications (1)

Publication Number Publication Date
AR095081A1 true AR095081A1 (es) 2015-09-16

Family

ID=48189627

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100782A AR095081A1 (es) 2013-03-08 2014-03-10 Compuestos químicos

Country Status (17)

Country Link
US (2) US20160038598A1 (es)
EP (1) EP2964244B1 (es)
JP (1) JP6473421B2 (es)
KR (1) KR102191195B1 (es)
CN (1) CN105324120B (es)
AR (1) AR095081A1 (es)
AU (1) AU2014224219B2 (es)
BR (1) BR112015021709B8 (es)
CA (1) CA2903663C (es)
DK (1) DK2964244T3 (es)
ES (1) ES2781965T3 (es)
GB (1) GB201304245D0 (es)
MX (1) MX364396B (es)
PL (1) PL2964244T3 (es)
RU (1) RU2015142677A (es)
TW (1) TW201446269A (es)
WO (1) WO2014136100A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10174289B2 (en) 2014-05-28 2019-01-08 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
WO2016061464A1 (en) 2014-10-17 2016-04-21 Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intetine using pluripotent stem cells and methods of making and using same
GB201501025D0 (en) * 2015-01-21 2015-03-04 Sagetis Biotech Sl Chemical compounds
WO2017112704A1 (en) * 2015-12-23 2017-06-29 Viking Scientific, Inc. Hydrogel prodrug for treatment
CN105535994B (zh) * 2015-12-25 2018-01-19 华中科技大学同济医学院附属同济医院 一种治疗hpv感染的纳米粒制剂及其制备方法
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
KR102558606B1 (ko) 2016-12-05 2023-07-26 칠드런즈 호스피탈 메디칼 센터 결장 유사장기 및 이를 제조 및 사용하는 방법
CN106727313B (zh) * 2017-01-06 2020-04-10 国家纳米科学中心 一种载药聚合物纳米胶束及其制备方法和应用
GB201708203D0 (en) * 2017-05-22 2017-07-05 Sagetis Biotech Sl Chemical compounds
WO2019084229A1 (en) 2017-10-27 2019-05-02 Massachusetts Institute Of Technology POLY (BETA-AMINO ESTERS) AND USES THEREOF
US11041069B2 (en) 2017-11-03 2021-06-22 Massachusetts Institute Of Technology Gene delivery carrier
AU2019213290A1 (en) 2018-01-17 2020-08-06 Ixaka France SAS Polymer-encapsulated viral vectors for genetic therapy
WO2020243647A1 (en) * 2019-05-31 2020-12-03 Children’S Hospital Medical Center Polymer based cellular labeling, barcoding and assembly
AU2020349085A1 (en) * 2019-09-21 2022-04-28 Ixaka France DMSO-free synthesis of oligopeptide-modified poly(beta-amino ester)s and their use in nanoparticle delivery systems
CN115298315A (zh) 2019-11-15 2022-11-04 艾夏卡法国有限公司 用于体内基因治疗的聚合物封装病毒载体
WO2021255262A1 (en) 2020-06-19 2021-12-23 Sylentis Sau siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES
US20220153901A1 (en) * 2020-11-19 2022-05-19 Encapsys,LLC Poly Acrylate and Poly(Beta-Amino Ester) Capsules with Enhanced Degradability
EP4015634A1 (en) 2020-12-15 2022-06-22 Sylentis, S.A.U. Sirna and compositions for prophylactic and therapeutic treatment of virus diseases
CA3225817A1 (en) * 2021-07-26 2023-02-02 Salvador Borros Gomez Covalently coated adeno-associated virus vector for its use in gene therapy
EP4166594A1 (en) 2021-10-14 2023-04-19 Institut Químic de Sarrià CETS Fundació Privada Zwitterionic functionalized poly(beta-aminoester) polymers and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010079526A (ko) * 1998-07-13 2001-08-22 추후제출 용해성 생분해 유전자 전달 담체인 폴리-ｌ-리신의폴리에스테르 유사체
US7427394B2 (en) * 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
DK1796650T3 (da) * 2004-09-14 2009-03-09 Nanodel Technologies Gmbh Transport- og afgivelsesvehikel indeholdende nanopartikler
US8071082B2 (en) * 2006-07-21 2011-12-06 Massachusetts Institute Of Technology End-modified poly(beta-amino esters) and uses thereof
US9717694B2 (en) * 2009-05-15 2017-08-01 The Johns Hopkins University Peptide/particle delivery systems
GB0913442D0 (en) * 2009-07-31 2009-09-16 Univ Ramot Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
US20140294909A1 (en) * 2011-10-13 2014-10-02 The Johns Hopkins University Nanocomposites of gold and polymers

Also Published As

Publication number Publication date
BR112015021709B8 (pt) 2022-04-05
US20160038598A1 (en) 2016-02-11
WO2014136100A1 (en) 2014-09-12
CN105324120A (zh) 2016-02-10
MX364396B (es) 2019-04-25
ES2781965T3 (es) 2020-09-09
AU2014224219A1 (en) 2015-09-24
DK2964244T3 (da) 2020-04-06
EP2964244A1 (en) 2016-01-13
BR112015021709B1 (pt) 2022-03-03
CA2903663C (en) 2022-08-30
AU2014224219B2 (en) 2018-12-13
GB201304245D0 (en) 2013-04-24
KR20150135334A (ko) 2015-12-02
BR112015021709A2 (pt) 2017-07-18
TW201446269A (zh) 2014-12-16
PL2964244T3 (pl) 2020-08-24
EP2964244B1 (en) 2020-01-08
JP6473421B2 (ja) 2019-02-20
JP2016511316A (ja) 2016-04-14
MX2015011393A (es) 2016-06-06
CA2903663A1 (en) 2014-09-12
RU2015142677A (ru) 2017-04-13
CN105324120B (zh) 2021-04-02
KR102191195B1 (ko) 2020-12-16
US20180250410A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
AR095081A1 (es) Compuestos químicos
AR105223A1 (es) Compuestos químicos
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
CO7151487A2 (es) Formulación de anticuerpos
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
CR20160117A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
CR20150604A (es) Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos
MX2014009480A (es) Metodo compartimentado de administracion de acidos nucleicos y composiciones y usos del mismo.
GT201200069A (es) Formulaciones farmacéuticas muy concentradas
UY35703A (es) Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos
AR096203A1 (es) Dosificaciones y métodos para administrar moléculas de ácido nucleico formuladas en lípidos
CL2014003509A1 (es) Composición veterinaria masticable blanda que comprende como agente activo un compuesto derivado de isoxazolina; y su uso para el tratamiento y/o prevención de una infestación y/o infección por parásitos en un animal (div. sol. n°2087-14).
CO7111300A2 (es) Formulación de anticuerpos
ECSP15004752A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
UY36467A (es) Composición farmacéutica que comprende plasminógeno y usos de este
EA201690967A1 (ru) Глазное устройство
CY1120488T1 (el) Υγρη φαρμακευτικη συνθεση
CR20140475A (es) Agentes terapéuticos para administración subcutánea optimizados
BR112017003219A2 (pt) formulação de acetato de abiraterona e métodos de uso
AR072668A1 (es) Encapsulacion de agentes biologicamente activos
MX2016012319A (es) Formulaciones antihelminticas veterinarias estables.
MX2018006226A (es) Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo.
CL2019003463A1 (es) Composición farmacéutica y forma de dosis farmacéutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenzamida, proceso para su preparación, métodos para tratamiento y usos de estas.

Legal Events

Date Code Title Description
FG Grant, registration